Meeting Banner
Abstract #0230

Amide-Proton-Transfer-Weighted (APTw) MRI as a Surrogate Biomarker to Detect Recurrent High-grade Gliomas after Treatment with Chemoradiation: Validation by Image-Guided Stereotactic Biopsy

Shanshan Jiang1,2, Charles Eberhart3, Jaishri Blakeley4, Lindsay Blair4, Huamin Qin 3, Michael Lim5, Alfredo Quinones-Hinojosa5, Hye-Young Heo1, Yi Zhang1, Dong-Hoon Lee1, Xuna Zhao1, Zhibo Wen2, Peter C.M. van Zijl1, and Jinyuan Zhou1

1Department of Radiology, Johns Hopkins University, Baltimore, MD, United States, 2Department of Radiology, Southern Medical University Zhujiang Hospital, Guangzhou, China, People's Republic of, 3Department of Pathology, Johns Hopkins University, Baltimore, MD, United States, 4Department of Neurology, Johns Hopkins University, Baltimore, MD, United States, 5Department of Neurosurgery, Johns Hopkins University, Baltimore, MD, United States

We explored the imaging features of treatment effects and active tumor in glioma patients after surgery and chemoradiation using amide-proton-transfer-weighted (APTw) imaging at 3 Tesla. Needle biopsy samples were obtained for pathological validation. Corresponding APTw signal intensities were recorded. Results showed that APTw signal intensities had strong positive correlations with cellularity and proliferation. The active tumor had significantly higher APTw signal intensity, compared to treatment effects. The area-under-curve (AUC) for APTw intensities to differentiate treatment effects from active tumor was 0.959. APT imaging has potential for molecular image-guided biopsy for post-treatment glioma patients to distinguish pseudoprogression from tumor recurrence.

This abstract and the presentation materials are available to members only; a login is required.

Join Here